Although Aurora Biosciences Corp. has by no means abandoned its toolkit services business, the company last week took steps toward becoming an integrated drug discovery company with a deal to identify, optimize and develop two to three candidate compounds to treat cystic fibrosis (CF) for the Cystic Fibrosis Foundation.

"This deal is a good example of Aurora taking its technology downstream," said ABSC Chairman, President and CEO Stuart Collinson. "We haven't traditionally performed compound identification."